1. Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophr Bull. 2021 Jul 8;47(4):1116–29.
2. Read J. The experiences of 585 people when they tried to withdraw from antipsychotic drugs. Addict Behav Rep. 2022 Jun;15:100421.
3. Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. Ther Adv Psychopharmacol. 2020 Jan;10:204512532093791.
4. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283–306.
5. Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom. 2017;86(4):189–219.
6. Brandt L, Bschor T, Henssler J, Müller M, Hasan A, Heinz A, Gutwinski S. Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis. Front Psychiatry. 2020 Sep 29;11:569912. doi: 10.3389/fpsyt.2020.569912. PMID: 33132934; PMCID: PMC7552943.
7. Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020 Dec 23;11:595584.
8. Zhou J, Zhu T, Zhu X, Galling B, Xiao L. Factors associated with antipsychotic use in non-psychotic depressed patients: results from a clinical multicenter survey. BMC Psychiatry. 2022 Feb 3;22(1):80.
9. Holm M, Tanskanen A, Lähteenvuo M, Tiihonen J, Taipale H. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder. Eur Neuropsychopharmacol. 2022 Aug 1;61:36–42.
10. Mann SK, Marwaha R. Chlorpromazine. [Updated 2022 May 17]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK553079/
11. Bogers JPAM, Hambarian G, Michiels M, Vermeulen J, de Haan L. Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull Open. 2020 Jan 1;1(1):sgaa002.
12. Steingard S. Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center. Community Ment Health J. 2018;54(8).
13. Liu C, Takeuchi H. Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm. CNS Drugs. 2020;34(2).